Patents by Inventor Ehud Goldin
Ehud Goldin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240025970Abstract: Described are heat stable protein-phospholipid concentrates within lung surfactant therapeutic compositions for the treatment of respiratory diseases in premature infants, children and adults. The concentrates can be suitable for localized delivery with improved transport to and spreadability within the lung and other tissues resulting in greater efficacy and efficiency of treatment.Type: ApplicationFiled: October 17, 2021Publication date: January 25, 2024Inventors: Sherwood Russ Lehrman, Ehud Goldin
-
Patent number: 10925874Abstract: Substituted pyrazolopyrimidines and dihydropyrazolopyrimidines and related compounds, their methods of manufacture, compositions containing these compounds, and methods of use of these compounds in treating lysosomal storage disorders such as Gaucher disease are described herein. The compounds are of general Formula (I) in which variables R1-R7 and X are described in the application.Type: GrantFiled: May 18, 2018Date of Patent: February 23, 2021Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Juan Jose Marugan, Noel Southall, Ehud Goldin, Wei Zheng, Samarjit Patnaik, Ellen Sidransky, Omid Motabar, Wendy Westbroek
-
Publication number: 20180263988Abstract: Substituted pyrazolopyrimidines and dihydropyrazolopyrimidines and related compounds, their methods of manufacture, compositions containing these compounds, and methods of use of these compounds in treating lysosomal storage disorders such as Gaucher disease are described herein. The compounds are of general Formula (I) in which variables R1-R7 and X are described in the application.Type: ApplicationFiled: May 18, 2018Publication date: September 20, 2018Inventors: Juan Jose Marugan, Noel Southall, Ehud Goldin, Wei Zheng, Samarjit Patnaik, Ellen Sidransky, Omid Motabar, Wendy Westbroek
-
Patent number: 9974789Abstract: Substituted pyrazolopyrimidines and dihydropyrazolopyrimidines and related compounds, their methods of manufacture, compositions containing these compounds, and methods of use of these compounds in treating lysosomal storage disorders such as Gaucher disease are described herein. The compounds are of general Formula (I) in which variables R1-R7 and X are described in the application.Type: GrantFiled: April 28, 2016Date of Patent: May 22, 2018Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Juan Jose Marugan, Noel Southall, Ehud Goldin, Wei Zheng, Samarjit Patnaik, Ellen Sidransky, Omid Motabar, Wendy Westbroek
-
Publication number: 20160346284Abstract: Substituted pyrazolopyrimidines and dihydropyrazolopyrimidines and related compounds, their methods of manufacture, compositions containing these compounds, and methods of use of these compounds in treating lysosomal storage disorders such as Gaucher disease are described herein. The compounds are of general Formula (I) in which variables R1-R7 and X are described in the application.Type: ApplicationFiled: April 28, 2016Publication date: December 1, 2016Inventors: Juan Jose Marugan, Noel Southall, Ehud Goldin, Wei Zheng, Samarjit Patnaik, Ellen Sidransky, Omid Motabar, Wendy Westbroek
-
Patent number: 9464035Abstract: Compounds of Formula (I) and the pharmaceutically acceptable salts thereof are disclosed. The variables. R1-R13, m, n, o, and p are disclosed herein. The compounds are useful for treating Gaucher disease and inhibiting the onset of Gaucher disease symptoms in a patient having a GBA gene mutation and for treating Parkinson's disease. Pharmaceutical compositions containing compounds of Formula (I) and methods of treatment comprising administering compounds of Formula (I) are also disclosed.Type: GrantFiled: March 15, 2013Date of Patent: October 11, 2016Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE UNIVERSITY OF KANSASInventors: Juan Jose Marugan, Wei Zheng, Samarjit Patnaik, Noel Southall, Ellen Sidransky, Ehud Goldin, Wendy Westbroek, Elma Aflaki, Steven Andrew Rogers, Frank John Schoenen
-
Patent number: 9353117Abstract: Substituted pyrazolopyrimidines and dihydropyrazolopyrimidines and related compounds, their methods of manufacture, compositions containing these compounds, and methods of use of these compounds in treating lysosomal storage disorders such as Gaucher disease are described herein. The compounds are of general Formula (I) in which variables R1-R7 and X are described in the application.Type: GrantFiled: December 8, 2011Date of Patent: May 31, 2016Assignee: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICESInventors: Juan Jose Marugan, Noel Southall, Ehud Goldin, Wei Zheng, Samarjit Patnaik, Ellen Sidransky, Omid Motabar, Wendy Westbroek
-
Publication number: 20150065469Abstract: Compounds of Formula (I) and the pharmaceutically acceptable salts thereof are disclosed. The variables. R1-R13, m, n, o, and p are disclosed herein. The compounds are useful for treating Gaucher disease and inhibiting the onset of Gaucher disease symptoms in a patient having a GBA gene mutation and for treating Parkinson's disease. Pharmaceutical compositions containing compounds of Formula (I) and methods of treatment comprising administering compounds of Formula (I) are also disclosed.Type: ApplicationFiled: March 15, 2013Publication date: March 5, 2015Inventors: Juan Jose Marugan, Wei Zheng, Samarjit Patnaik, Noel Southall, Ellen Sidransky, Ehud Goldin, Wendy Westbroek, Elma Aflaki, Steven Andrew Rogers, Frank John Schoenen
-
Publication number: 20140249145Abstract: Substituted pyrazolopyrimidines and dihydropyrazolopyrimidines and related compounds, their methods of manufacture, compositions containing these compounds, and methods of use of these compounds in treating lysosomal storage disorders such as Gaucher disease are described herein. The compounds are of general Formula (I) in which variables R1-R7 and X are described in the application.Type: ApplicationFiled: December 8, 2011Publication date: September 4, 2014Applicant: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human ServInventors: Juan Jose Marugan, Noel Southall, Ehud Goldin, Wei Zheng, Samarjit Patnaik, Ellen Sidransky, Omid Motabar, Wendy Westbroek
-
Publication number: 20100267582Abstract: Methods are provided for evaluating a stroke, for example for determining whether a subject has had an ischemic stroke, determining the severity or likely neurological recovery of a subject who has had an ischemic stroke, and determining a treatment regimen for a subject who has had an ischemic stroke, as are arrays and kits that can be used to practice the methods. In particular examples, the method includes screening for expression in ischemic stroke related genes (or proteins), such as white blood cell activation and differentiation genes (or proteins), genes (or proteins) related to hypoxia, genes (or proteins) involved in vascular repair, and genes (or proteins) related to a specific peripheral blood mononuclear cell (PBMC) response to the altered cerebral microenvironment. Also provided are methods of identifying one or more agents that alter the activity (such as the expression) of an ischemic stroke-related molecule.Type: ApplicationFiled: July 1, 2010Publication date: October 21, 2010Inventors: ALISON E. BAIRD, DAVID F. MOORE, EHUD GOLDIN
-
Patent number: 7749700Abstract: Methods are provided for evaluating a stroke, for example for determining whether a subject has had an ischemic stroke, determining the severity or likely neurological recovery of a subject who has had an ischemic stroke, and determining a treatment regimen for a subject who has had an ischemic stroke, as are arrays and kits that can be used to practice the methods. In particular examples, the method includes screening for expression in ischemic stroke related genes (or proteins), such as white blood cell activation and differentiation genes (or proteins), genes (or proteins) related to hypoxia, genes (or proteins) involved in vascular repair, and genes (or proteins) related to a specific peripheral blood mononuclear cell (PBMC) response to the altered cerebral microenvironment. Also provided are methods of identifying one or more agents that alter the activity (such as the expression) of an ischemic stroke-related molecule.Type: GrantFiled: June 17, 2005Date of Patent: July 6, 2010Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Alison E. Baird, David F. Moore, Ehud Goldin
-
Publication number: 20100086481Abstract: Methods are provided for evaluating a stroke, for example for determining whether a subject has had a hemorrhagic stroke, determining the severity or likely neurological recovery of a subject who has had a hemorrhagic stroke, and determining a treatment regimen for a subject who has had a hemorrhagic stroke, as are arrays and kits that can be used to practice the methods. In particular examples, the method includes screening for expression of hemorrhagic stroke related genes (or proteins), such as genes (or proteins) involved in suppression of the immune response, genes (or proteins) involved in vascular repair, genes (or proteins) involved in the acute inflammatory response, genes (or proteins) involved in cell adhesion, genes (or proteins) involved in hypoxia, genes (or proteins) involved in signal transduction, and genes (or proteins) involved in the response to the altered cerebral microenvironment. Arrays and kits are provided that can be used in the disclosed methods.Type: ApplicationFiled: July 11, 2007Publication date: April 8, 2010Inventors: Alison E. Baird, David F. Moore, Ehud Goldin, Kory Johnson
-
Patent number: 7041448Abstract: The present invention relates to identification of a gene that is inactivated in a mucolipidosis condition. In particular, the invention concerns mutations that disrupt a mucolipin, preferably MCOLN1, in mucolipidosis IV. Recombinant nucleic acids encoding mutant forms of MCOLN1, oligonucleotides specific for such mutations, and diagnostic and therapeutic applications related to these discoveries, are also contemplated.Type: GrantFiled: May 8, 2001Date of Patent: May 9, 2006Assignees: The ML4 Foundation, The General Hospital CorporationInventors: Ehud Goldin, Susan A. Slaugenhaupt, Mei Sun, James S. Acierno, Jr.
-
Publication number: 20060046259Abstract: Methods are provided for evaluating a stroke, for example for determining whether a subject has had an ischemic stroke, determining the severity or likely neurological recovery of a subject who has had an ischemic stroke, and determining a treatment regimen for a subject who has had an ischemic stroke, as are arrays and kits that can be used to practice the methods. In particular examples, the method includes screening for expression in ischemic stroke related genes (or proteins), such as white blood cell activation and differentiation genes (or proteins), genes (or proteins) related to hypoxia, genes (or proteins) involved in vascular repair, and genes (or proteins) related to a specific peripheral blood mononuclear cell (PBMC) response to the altered cerebral microenvironment. Also provided are methods of identifying one or more agents that alter the activity (such as the expression) of an ischemic stroke-related molecule.Type: ApplicationFiled: June 17, 2005Publication date: March 2, 2006Inventors: Alison Baird, David Moore, Ehud Goldin
-
Publication number: 20030064363Abstract: The present invention relates to identification of a gene that is inactivated in a mucolipidosis condition. In particular, the invention concerns mutations that disrupt a mucolipin, preferably MCOLN1, in mucolipidosis IV. Recombinant nucleic acids encoding mutant forms of MCOLN1, oligonucleotides specific for such mutations, and diagnostic and therapeutic applications related to these discoveries, are also contemplated.Type: ApplicationFiled: May 8, 2001Publication date: April 3, 2003Applicant: The ML4 Foundation and President and Fellows of Havard CollegeInventors: Ehud Goldin, Susan A. Slaugenhaupt, Mei Sun, James S. Acierno